Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory bowel disease and treatments for other chronic diseases.
WISH-TV on MSN2h
Lilly to acquire biopharmaceutical company Morphic; aims to improve results for IBD patientsEli Lilly and Company announced Monday morning that it has reached an agreement to acquire biopharmaceutical company Morphic.
Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation.
Massachusetts-based Morphic Holding Inc. is a nine-year old, publicly traded company that is developing a class of drugs known as oral integrin therapies to treat autoimmune diseases, pulmonary ...
Branded as Kisunla by drugmaker Eli Lilly, donanemab's approval follows years of setbacks and delays in getting the ...
Wall Street expectations for where Eli Lilly stock is headed this year vary considerably, but some analysts still have faith.
Shares of Novo Nordisk and Eli Lilly & Co. dropped early Tuesday after President Joe Biden and Sen. Bernie Sanders criticized ...
Tesla stock surges after the electric-vehicle maker’s second-quarter deliveries top estimates, and Nvidia shares move lower ...
With a rich history dating back to the 19th century, Eli Lilly (LLY) has faced struggles and successes. But a booming market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback